Clinical Trials Directory

Trials / Unknown

UnknownNCT05482867

Exploratory Open Label Study for Development of a Method To Detect Dendritic Cells

Exploratory Open-Label Study For the Development of a Method To Detect Dendritic Cell Recruitment in Alzheimer's Disease (DC RAD)

Status
Unknown
Phase
Study type
Observational
Enrollment
45 (estimated)
Sponsor
MindImmune Therapeutics, Inc. · Industry
Sex
All
Age
21 Years – 90 Years
Healthy volunteers
Accepted

Summary

This is a proof-of-concept study designed to confirm that human phagocytic cells can be labeled with the near-infrared dye indocyanine green (ICG) and the presence of the labeled cells 48 hours later in cerebral cortex can be inferred using near infrared spectroscopy (NIRS).

Detailed description

To develop a method to detect dendritic cell recruitment in Alzheimer's disease (DC RAD), this study is designed in 2 parts. The first part assesses the safety and efficacy of indocyanine green (ICG) in labeling peripheral immune phagocytic cells in healthy adult subjects. The second part is designed to determine the presence of ICG in the brain of adult subjects diagnosed with Alzheimer's disease (AD). In the first part of the study, ICG will be delivered by intravenous infusion to healthy subjects to verify that peripheral immune phagocytic cells, of which DCs are a subset, can be labeled with ICG. If ICG labeling of phagocytic cells is confirmed, then in the second part of the study the presence of ICG in brain of AD patients, putatively carried in by ICG-labeled cells, will be investigated by NIRS using the INVOS 7000 cerebral oximeter.

Conditions

Timeline

Start date
2022-11-09
Primary completion
2023-06-15
Completion
2023-07-15
First posted
2022-08-01
Last updated
2022-11-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05482867. Inclusion in this directory is not an endorsement.